Mathematical model of triple-negative breast cancer in response to combination chemotherapies
From MaRDI portal
Publication:2111185
Recommendations
- Model selection for assessing the effects of doxorubicin on triple-negative breast cancer cell lines
- A prognostic immunotherapy model for 4T1 breast cancer with combined cyclophosphamide and TLR agonist
- Mathematical modeling of ER-positive breast cancer treatment with AZD9496 and palbociclib
- Mathematical modelling of trastuzumab-induced immune response in an \textit{in vivo} murine model of HER2+ breast cancer
- Optimizing combination therapy in a murine model of HER2+ breast cancer
Cites work
- A framework for model analysis across multiple experiment regimes: investigating effects of zinc on \textit{Xylella fastidiosa} as a case study
- A mathematical model of breast cancer treatment with CMF and doxorubicin
- A reduced mathematical model of the acute inflammatory response. I: Derivation of model and analysis of anti-inflammation
- A reduced mathematical model of the acute inflammatory response. II: Capturing scenarios of repeated endotoxin administration
- Global sensitivity indices for nonlinear mathematical models and their Monte Carlo estimates
- Macrophage-tumour interactions: In vivo dynamics
- Making best use of model evaluations to compute sensitivity indices
- Mathematical modeling of therapeutic neural stem cell migration in mouse brain with and without brain tumors
- Mathematical modelling of trastuzumab-induced immune response in an \textit{in vivo} murine model of HER2+ breast cancer
- Nonlinear simulation of the effect of microenvironment on tumor growth
- Sensitivity measures,anova-like Techniques and the use of bootstrap
Cited in
(12)- Mathematical model for the estrogen paradox in breast cancer treatment
- Data-based modeling of breast cancer and optimal therapy
- scientific article; zbMATH DE number 2149590 (Why is no real title available?)
- Understanding the interplay of CAR-NK cells and triple-negative breast cancer: insights from computational modeling
- Deconstructing the contributions of heterogeneity to combination treatment of hormone-sensitive breast cancer
- Mathematical modeling of ER-positive breast cancer treatment with AZD9496 and palbociclib
- A prognostic immunotherapy model for 4T1 breast cancer with combined cyclophosphamide and TLR agonist
- Optimizing combination therapy in a murine model of HER2+ breast cancer
- A mathematical model for the effects of HER2 overexpression on cell proliferation in breast cancer
- Mathematical modelling of trastuzumab-induced immune response in an \textit{in vivo} murine model of HER2+ breast cancer
- A mathematical model of breast cancer treatment with CMF and doxorubicin
- Model selection for assessing the effects of doxorubicin on triple-negative breast cancer cell lines
This page was built for publication: Mathematical model of triple-negative breast cancer in response to combination chemotherapies
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2111185)
